Unmet Needs in the Treatment of Patients With Metastatic Breast Cancer With Visceral Metastases
Virginia Kaklamani, MD, DSc, reviews the presented case of a postmenopausal patient with breast cancer who develops metastases after adjuvant endocrine therapy ends, and explains that later treatment selection is difficult because of endocrine resistance and mutations causing more aggressive disease.
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
